Work

33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)

Year: 2022

Type: article

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2022.06.731

Authors: April Armstrong, Sandra McBride, Lynda Spelman, Pablo Fernández-Peñas, Phoebe Rich, George Martin, Nicola Tilt, Jose M. Lopez Pinto, Christina Popova, Scarlett Hellot

Institutions: University of Southern California, Royal Free London NHS Foundation Trust, Veracity Clinical Research, The University of Sydney, Westmead Hospital, Oregon Dermatology & Research Center, UCB Pharma (United Kingdom), UCB Pharma (Belgium), University Hospital Bonn

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4295255182

FWCI: 0.153

Cites:

Cited by: 3

Related to: 10